| |
| |
|
| Insider
Information: |
Clague Laura |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
424,757 |
|
|
Indirect Shares
|
2,000 |
|
|
| Direct
Value |
$1,037,526 |
|
|
|
Indirect Value
|
$3,800 |
|
|
| Total
Shares |
426,757 |
|
|
| Total
Value |
$1,041,326 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
0
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -32.4%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Genasys Inc |
GNSS |
Director |
2022-04-27 |
284,311 |
2022-04-27 |
2,000 |
Premium* |
|
|
Travere Therapeutics, Inc |
TVTX |
Chief Financial Officer |
2022-05-11 |
35,655 |
2018-02-08 |
0 |
Premium* |
|
|
Fluidigm Corp |
FLDM |
Director |
2023-06-14 |
104,791 |
2018-10-30 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
65 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2020-11-24 |
4 |
AS |
$23.86 |
$89,475 |
D/D |
(3,750) |
23,223 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2020-11-25 |
4 |
AS |
$22.72 |
$85,200 |
D/D |
(3,750) |
19,473 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2021-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
34,473 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2021-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
39,473 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2021-02-02 |
4 |
AS |
$30.75 |
$111,469 |
D/D |
(3,625) |
35,848 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
36,723 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2021-02-03 |
4 |
AS |
$28.91 |
$104,799 |
D/D |
(3,625) |
32,223 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2021-02-05 |
4 |
AS |
$31.41 |
$70,673 |
D/D |
(2,250) |
34,473 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2021-02-08 |
4 |
AS |
$31.58 |
$71,055 |
D/D |
(2,250) |
32,223 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2021-05-11 |
4 |
AS |
$19.14 |
$38,280 |
D/D |
(2,000) |
30,223 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2021-05-12 |
4 |
AS |
$19.46 |
$38,920 |
D/D |
(2,000) |
28,223 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2021-08-13 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
32,723 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2021-08-17 |
4 |
S |
$17.12 |
$24,085 |
D/D |
(1,407) |
31,316 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2022-01-10 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
38,816 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2022-01-11 |
4 |
AS |
$27.40 |
$205,500 |
D/D |
(7,500) |
31,316 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2022-01-24 |
4 |
AS |
$24.98 |
$51,534 |
D/D |
(2,063) |
29,253 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2022-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
9,840 |
39,093 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2022-01-31 |
4 |
AS |
$27.40 |
$33,921 |
D/D |
(1,238) |
37,855 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2022-05-10 |
4 |
AS |
$21.51 |
$17,746 |
D/D |
(825) |
37,030 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
• – – |
2022-05-11 |
4 |
AS |
$21.51 |
$29,576 |
D/D |
(1,375) |
35,655 |
0 |
% |
|
| GNSS |
Genasys Inc |
Director |
– • – |
2008-12-11 |
4 |
B |
$0.43 |
$870 |
I/I |
2,000 |
2,000 |
2.02 |
- |
|
| GNSS |
Genasys Inc |
Director |
• • – |
2017-05-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
47,600 |
0 |
- |
|
| GNSS |
Genasys Inc |
Director |
• • – |
2018-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
70,600 |
0 |
- |
|
| FLDM |
Fluidigm Corp |
Director |
– • – |
2018-10-30 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
0 |
- |
|
| GNSS |
Genasys Inc |
Director |
• • – |
2019-03-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
95,600 |
0 |
- |
|
65 Records found
|
|
Page 2 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
